Remogliflozin etabonate
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models[1].
Product Specifications
CAS Number
442201-24-3
Product Name Alternative
GSK189075
UNSPSC
12352005
Target
SGLT
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/remogliflozin-etabonate.html
Purity
99.81
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CCOC(OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC2=NN(C(C)C)C(C)=C2CC3=CC=C(OC(C)C)C=C3)=O
Molecular Formula
C26H38N2O9
Molecular Weight
522.59
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
SGLT1; SGLT2
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MUC18 / Mucin 18 / CD146 (OJ79c), CF405S conjugate, 0.1mg/mL
CD31 / PECAM-1 (158-2B3), CF568 conjugate, 0.1mg/mL
Pmel17 / gp100 / SILV (NKI-beteb), CF640R conjugate, 0.1mg/mL
